Hetero-oligomerization of chemokine receptors: Diversity and relevance for function

Current Medicinal Chemistry

Volumn 20, Issue 20, 2013, Pages 2524-2536

  Kraemer, S ^a   Alampour Rajabi, S ^a   Bounkari, O El ^a   Bernhagen, J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

CC chemokine; Crosstalk; CXC chemokine; GPCR; Hetero dimerization; Homo dimerization; MIF receptors; Signaling

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; PROTEIN KINASE ZAP 70; RANTES; STROMAL CELL DERIVED FACTOR 1ALPHA;

ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; ENDOPLASMIC RETICULUM; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; INTERNALIZATION; LIGAND BINDING; MACROPHAGE; MEMORY T LYMPHOCYTE; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OLIGOMERIZATION; POINT MUTATION; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STOICHIOMETRY;

CHEMOKINES; HUMANS; PROTEIN MULTIMERIZATION; RECEPTORS, CCR; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84877995317     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990117     Document Type: Article

References (141)

1. Baggiolini M.; Dewald B.; Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 1994 55 97-179.
2. Charo I. F.; Ransohoff R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006 354 (6) 610-621.
3. Charo I. F.; Taubman M. B. Chemokines in the pathogenesis of vascular disease. Circ. Res. 2004 95 (9) 858-866.
4. Hansson G. K. Inflammation and immune response in atherosclerosis. Curr. Atheroscler. Rep. 1999 1 (2) 150-155.
5. Mackay C. R. Chemokines: immunology's high impact factors. Nat. Immunol. 2001 2 (2) 95-101.
6. Moser B.; Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2001 2 (2) 123-128.
7. Moser B.; Wolf M.; Walz A.; Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004 25 (2) 75-84.
8. Rot A.; von Andrian U. H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 2004 22 891-928. (Pubitemid 38680444)
9. Schober A.; Weber C. Mechanisms of monocyte recruitment in vascular repair after injury. Antioxid. Redox. Signal. 2005 7 (9-10) 1249-1257. (Pubitemid 41232521)
10. Thelen M.; Stein J. V. How chemokines invite leukocytes to dance. Nat. Immunol. 2008 9 (9) 953-959.
11. Zernecke A.; Shagdarsuren E.; Weber C. Chemokines in atherosclerosis: An update. Arterioscler. Thromb. Vasc. Biol. 2008 28 (11) 1897-1908.
12. Sallusto F.; Baggiolini M. Chemokines and leukocyte traffic. Nat. Immunol. 2008 9 (9) 949-952.
13. Ley K. Arrest chemokines. Microcirculation 2003 10 (3-4) 289-295. (Pubitemid 39004256)
14. Murphy P. M.; Baggiolini M.; Charo I. F.; Hebert C. A.; Horuk R.; Matsushima K.; Miller L. H.; Oppenheim J. J.; Power C. A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000 52 (1) 145-176.
15. Thelen M. Dancing to the tune of chemokines. Nat. Immunol. 2001 2 (2) 129-134. (Pubitemid 33707930)
16. Luster A. D. Chemokines -chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998 338 436-445. (Pubitemid 28135672)
17. Noels H.; Bernhagen J.; Weber C. Macrophage migration inhibitory factor: A noncanonical chemokine important in atherosclerosis. Trends. Cardiovasc. Med. 2009 19 (3) 76-86.
18. Oppenheim J. J.; Biragyn A.; Kwak L. W.; Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 2003 62 Suppl 2 ii17-21. (Pubitemid 37323593)
19. Yang D.; Biragyn A.; Hoover D. M.; Lubkowski J.; Oppenheim J. J. Multiple roles of antimicrobial defensins cathelicidins and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 2004 22 181-215. (Pubitemid 38680422)
20. Yang D.; Oppenheim J. J. Antimicrobial proteins act as alarmins in joint immune defense. Arthritis Rheum. 2004 50 (11) 3401-3403. (Pubitemid 39488662)
21. Oppenheim J. J.; Dong H. F.; Plotz P.; Caspi R. R.; Dykstra M.; Pierce S.; Martin R.; Carlos C.; Finn O.; Koul O.; Howard O. M. Autoantigens act as tissue-specific chemoattractants. J. Leukoc. Biol. 2005 77 (6) 854-861. (Pubitemid 40770835)
22. Oppenheim J. J.; Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 2005 17 (4) 359-365. (Pubitemid 40848537)
23. Degryse B.; de Virgilio M. The nuclear protein HMGB1 a new kind of chemokine? FEBS. Lett. 2003 553 (1-2) 11-17. (Pubitemid 37206316)
24. Weber C.; Koenen R. R. Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends. Immunol. 2006 27 (6) 268-273. (Pubitemid 43850403)
25. Veldkamp C. T.; Peterson F. C.; Pelzek A. J.; Volkman B. F. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH phosphate sulfate and heparin. Protein Sci. 2005 14 (4) 1071-1081. (Pubitemid 40389378)
26. Veldkamp C. T.; Ziarek J. J.; Su J.; Basnet H.; Lennertz R.; Weiner J. J.; Peterson F. C.; Baker J. E.; Volkman B. F. Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12. Protein Sci. 2009 18 (7) 1359-1369.
27. Murphy J. W.; Cho Y.; Sachpatzidis A.; Fan C.; Hodsdon M. E.; Lolis E. Structural and functional basis of CXCL12 (stromal cellderived factor-1 alpha) binding to heparin. J. Biol. Chem. 2007 282 (13) 10018-10027. (Pubitemid 47104591)
28. Nasser M. W.; Raghuwanshi S. K.; Grant D. J.; Jala V. R.; Rajarathnam K.; Richardson R. M. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J. Immunol. 2009 183 (5) 3425-3432.
29. Ravindran A.; Joseph P. R.; Rajarathnam K. Structural basis for differential binding of the interleukin-8 monomer and dimer to the CXCR1 N-domain: role of coupled interactions and dynamics. Biochemistry 2009 48 (37) 8795-8805.
30. Koenen R. R.; von Hundelshausen P.; Nesmelova I. V.; Zernecke A.; Liehn E. A.; Sarabi A.; Kramp B. K.; Piccinini A. M.; Paludan S. R.; Kowalska M. A.; Kungl A. J.; Hackeng T. M.; Mayo K. H.; Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 2009 15 (1) 97-103.
31. Nesmelova I. V.; Sham Y.; Dudek A. Z.; van Eijk L. I.; Wu G.; Slungaard A.; Mortari F.; Griffioen A. W.; Mayo K. H. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J. Biol. Chem. 2005 280 (6) 4948-4958. (Pubitemid 40288670)
32. Nesmelova I. V.; Sham Y.; Gao J.; Mayo K. H. CXC and CC chemokines form mixed heterodimers: Association free energies from molecular dynamics simulations and experimental correlations. J. Biol. Chem. 2008 283 (35) 24155-24166.
33. St Charles R.; Walz D. A.; Edwards B. F. The three-dimensional structure of bovine platelet factor 4 at 3.0-A resolution. J. Biol. Chem. 1989 264 (4) 2092-2099. (Pubitemid 19057678)
34. Yang Y.; Mayo K. H.; Daly T. J.; Barry J. K.; La Rosa G. J. Subunit association and structural analysis of platelet basic protein and related proteins investigated by 1H NMR spectroscopy and circular dichroism. J. Biol. Chem. 1994 269 (31) 20110-20118. (Pubitemid 24250935)
35. Handel T. M.; Domaille P. J. Heteronuclear (1H 13C 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 1996 35 6569-6584.
36. Schiraldi M.; Raucci A.; Munoz L. M.; Livoti E.; Celona B.; Venereau E.; Apuzzo T.; De Marchis F.; Pedotti M.; Bachi A.; Thelen M.; Varani L.; Mellado M.; Proudfoot A.; Bianchi M. E.; Uguccioni M. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 2012 209 (3) 551-563.
37. Wu B.; Chien E. Y.; Mol C. D.; Fenalti G.; Liu W.; Katritch V.; Abagyan R.; Brooun A.; Wells P.; Bi F. C.; Hamel D. J.; Kuhn P.; Handel T. M.; Cherezov V.; Stevens R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010 330 (6007) 1066-1071.
38. Crump M. P.; Gong J. H.; Loetscher P.; Rajarathnam K.; Amara A.; Arenzana-Seisdedos F.; Virelizier J. L.; Baggiolini M.; Sykes B. D.; Clark-Lewis I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO. J. 1997 16 (23) 6996-7007. (Pubitemid 27520800)
39. Clark-Lewis I.; Kim K. S.; Rajarathnam K.; Gong J. H.; Dewald B.; Moser B.; Baggiolini M.; Sykes B. D. Structure-Activity relationships of chemokines. J. Leukoc. Biol. 1995 57 (5) 703-711.
40. Wells T. N.; Power C. A.; Lusti-Narasimhan M.; Hoogewerf A. J.; Cooke R. M.; Chung C. W.; Peitsch M. C.; Proudfoot A. E. Selectivity and antagonism of chemokine receptors. J. Leukoc. Biol. 1996 59 (1) 53-60. (Pubitemid 26057473)
41. Vila-Coro A. J.; Rodriguez-Frade J. M.; Martin De Ana A.; Moreno-Ortiz M. C.; Martinez A. C.; Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB. J. 1999 13 (13) 1699-1710. (Pubitemid 29473332)
42. Mellado M.; Rodriguez-Frade J. M.; Aragay A.; del Real G.; Martin A. M.; Vila-Coro A. J.; Serrano A.; Mayor F.; Martinez A. C. The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J. Immunol. 1998 161 (2) 805-813. (Pubitemid 28323544)
43. Luttrell L. M.; Ferguson S. S.; Daaka Y.; Miller W. E.; Maudsley S.; Della Rocca G. J.; Lin F.; Kawakatsu H.; Owada K.; Luttrell D. K.; Caron M. G.; Lefkowitz R. J. Beta-Arrestindependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999 283 (5402) 655-661.
44. Trettel F.; Di Bartolomeo S.; Lauro C.; Catalano M.; Ciotti M. T.; Limatola C. Ligand-independent CXCR2 dimerization. J. Biol. Chem. 2003 278 (42) 40980-40988. (Pubitemid 37280920)
45. Milligan G.; Wilson S.; Lopez-Gimenez J. F. The specificity and molecular basis of alpha1-Adrenoceptor and CXCR chemokine receptor dimerization. J Mol Neurosci 2005 26 (2-3) 161-168.
46. Wilson S.; Wilkinson G.; Milligan G. The CXCR1 and CXCR2 receptors form constitutive homo-And heterodimers selectively and with equal apparent affinities. J. Biol. Chem. 2005 280 (31) 28663-28674. (Pubitemid 41105767)
47. Lee J.; Horuk R.; Rice G. C.; Bennett G. L.; Camerato T.; Wood W. I. Characterization of two high affinity human interleukin-8 receptors. J. Biol. Chem. 1992 267 (23) 16283-16287.
48. Balabanian K.; Lagane B.; Infantino S.; Chow K. Y.; Harriague J.; Moepps B.; Arenzana-Seisdedos F.; Thelen M.; Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 2005 280 (42) 35760-35766. (Pubitemid 41532769)
49. Burns J. M.; Summers B. C.; Wang Y.; Melikian A.; Berahovich R.; Miao Z.; Penfold M. E.; Sunshine M. J.; Littman D. R.; Kuo C. J.; Wei K.; McMaster B. E.; Wright K.; Howard M. C.; Schall T. J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival cell adhesion and tumor development. J. Exp. Med. 2006 203 (9) 2201-2213. (Pubitemid 44352240)
50. Boldajipour B.; Mahabaleshwar H.; Kardash E.; Reichman-Fried M.; Blaser H.; Minina S.; Wilson D.; Xu Q.; Raz E. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008 132 (3) 463-473. (Pubitemid 351191997)
51. Thelen M.; Thelen S. CXCR7 CXCR4 and CXCL12: An eccentric trio? J. Neuroimmunol. 2008 198 (1-2) 9-13.
52. Levoye A.; Balabanian K.; Baleux F.; Bachelerie F.; Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009 113 (24) 6085-6093.
53. Sierro F.; Biben C.; Martinez-Munoz L.; Mellado M.; Ransohoff R. M.; Li M.; Woehl B.; Leung H.; Groom J.; Batten M.; Harvey R. P.; Martinez A. C.; Mackay C. R.; Mackay F. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor CXCR7. Proc. Natl. Acad. Sci. USA. 2007 104 (37) 14759-14764. (Pubitemid 350003216)
54. Luker K. E.; Gupta M.; Luker G. D. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB. J. 2009 23 (3) 823-834.
55. Sohy D.; Parmentier M.; Springael J.Y. Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J. Biol. Chem. 2007 282 (41) 30062-30069. (Pubitemid 350035295)
56. Percherancier Y.; Berchiche Y.A.; Slight I.; Volkmer-Engert R.; Tamamura H.; Fujii N.; Bouvier M.; Heveker N. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo-And heterodimers. J. Biol. Chem. 2005 280 (11) 9895-9903. (Pubitemid 40395837)
57. Rodriguez-Frade J. M.; del Real G.; Serrano A.; Hernanz-Falcon P.; Soriano S. F.; Vila-Coro A. J.; de Ana A. M.; Lucas P.; Prieto I.; Martinez A. C.; Mellado M. Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO. J. 2004 23 (1) 66-76. (Pubitemid 38165748)
58. El-Asmar L.; Springael J. Y.; Ballet S.; Andrieu E. U.; Vassart G.; Parmentier M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 2005 67 (2) 460-469. (Pubitemid 40216739)
59. Mellado M.; Rodriguez-Frade J. M.; Vila-Coro A. J.; Fernandez S.; Martin de Ana A.; Jones D. R.; Toran J. L.; Martinez A. C. Chemokine receptor homo-or heterodimerization activates distinct signaling pathways. EMBO. J. 2001 20 (10) 2497-2507. (Pubitemid 32452868)
60. Springael J. Y.; Le Minh P. N.; Urizar E.; Costagliola S.; Vassart G.; Parmentier M. Allosteric modulation of binding properties between units of chemokine receptor homo-And heterooligomers. Mol. Pharmacol. 2006 69 (5) 1652-1661.
61. Frade J. M.; Mellado M.; del Real G.; Gutierrez-Ramos J. C.; Lind P.; Martinez A. C. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J. Immunol. 1997 159 (11) 5576-5584. (Pubitemid 127470087)
62. Mellado M.; Rodriguez-Frade J. M.; Vila-Coro A. J.; de Ana A. M.; Martinez A. C. Chemokine control of HIV-1 infection. Nature 1999 400 (6746) 723-724.
63. Issafras H.; Angers S.; Bulenger S.; Blanpain C.; Parmentier M.; Labbe-Jullie C.; Bouvier M.; Marullo S. Constitutive agonistindependent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J. Biol. Chem. 2002 277 (38) 34666-34673.
64. Babcock G. J.; Farzan M.; Sodroski J. Ligand-independent dimerization of CXCR4 a principal HIV-1 coreceptor. J. Biol. Chem. 2003 278 (5) 3378-3385. (Pubitemid 36801253)
65. Contento R. L.; Molon B.; Boularan C.; Pozzan T.; Manes S.; Marullo S.; Viola A. CXCR4-CCR5: A couple modulating T cell functions. Proc Natl Acad Sci USA 2008 105 (29) 10101-10106.
66. Isik N.; Hereld D.; Jin T. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS. One 2008 3 (10) e3424.
67. Wang J.; Alvarez R.; Roderiquez G.; Guan E.; Norcross M. A. Constitutive association of cell surface CCR5 and CXCR4 in the presence of CD4. J. Cell Biochem. 2004 93 (4) 753-760. (Pubitemid 44264171)
68. Parenty G.; Appelbe S.; Milligan G. CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem. J. 2008 412 (2) 245-256. (Pubitemid 351758230)
69. Pello O. M.; Martinez-Munoz L.; Parrillas V.; Serrano A.; Rodriguez-Frade J. M.; Toro M. J.; Lucas P.; Monterrubio M.; Martinez A. C.; Mellado M. Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur. J. Immunol. 2008 38 (2) 537-549.
70. Finley M. J.; Chen X.; Bardi G.; Davey P.; Geller E. B.; Zhang L.; Adler M. W.; Rogers T. J. Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. J. Neuroimmunol. 2008 197 (2) 114-123.
71. McCarthy L.; Wetzel M.; Sliker J. K.; Eisenstein T. K.; Rogers T. J. Opioids opioid receptors and the immune response. Drug Alcohol Depend 2001 62 (2) 111-123. (Pubitemid 32195501)
72. Finley M. J.; Chen X.; Bardi G.; Davey P.; Geller E. B.; Zhang L.; Adler M. W.; Rogers T. J. Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. Neuroimmunol. 2008 197 (2) 114-123.
73. Chen C.; Li J.; Bot G.; Szabo I.; Rogers T.J.; Liu-Chen L. Y. Heterodimerization and cross-desensitization between the muopioid receptor and the chemokine CCR5 receptor. Eur. J. Pharmacol. 2004 483 (2-3) 175-186. (Pubitemid 38068398)
74. Suzuki S.; Chuang L. F.; Yau P.; Doi R. H.; Chuang R. Y. Interactions of opioid and chemokine receptors: oligomerization of mu kappa and delta with CCR5 on immune cells. Exp. Cell Res. 2002 280 (2) 192-200. (Pubitemid 35333761)
75. Szabo I.; Wetzel M. A.; Zhang N.; Steele A. D.; Kaminsky D. E.; Chen C.; Liu-Chen L. Y.; Bednar F.; Henderson E. E.; Howard O. M.; Oppenheim J. J.; Rogers T. J. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization. J. Leukoc. Biol. 2003 74 (6) 1074-1082. (Pubitemid 38040329)
76. Vischer H. F.; Nijmeijer S.; Smit M. J.; Leurs R. Viral hijacking of human receptors through heterodimerization. Biochem. Biophys. Res. Commun. 2008 377 (1) 93-97.
77. Nijmeijer S.; Leurs R.; Smit M. J.; Vischer H. F. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 heterooligomerizes with human CXCR4 scavenges Galphai proteins and constitutively impairs CXCR4 functioning. J. Biol. Chem. 2010 285 (38) 29632-29641.
78. Laichalk L. L.; Thorley-Lawson D. A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 2005 79 (2) 1296-1307. (Pubitemid 40053911)
79. Paulsen S. J.; Rosenkilde M. M.; Eugen-Olsen J.; Kledal T. N. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 2005 79 (1) 536-546. (Pubitemid 39648406)
80. Wetzker R.; Bohmer F. D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat. Rev. Mol. Cell Biol. 2003 4 (8) 651-657. (Pubitemid 36934967)
81. Schwartz V.; Lue H.; Kraemer S.; Korbiel J.; Krohn R.; Ohl K.; Bucala R.; Weber C.; Bernhagen J. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS. Lett. 2009 583 (17) 2749-2757.
82. Stumptner-Cuvelette P.; Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim. Biophys. Acta. 2002 1542 (1-3) 1-13.
83. Leng L.; Metz C.N.; Fang Y.; Xu J.; Donnelly S.; Baugh J.; Delohery T.; Chen Y.; Mitchell R. A.; Bucala R. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 2003 197 (11) 1467-1476. (Pubitemid 36686708)
84. Shi X.; Leng L.; Wang T.; Wang W.; Du X.; Li J.; McDonald C.; Chen Z.; Murphy J. W.; Lolis E.; Noble P.; Knudson W.; Bucala R. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006 25 (4) 595-606. (Pubitemid 44529040)
85. Ashman J. B.; Miller J. A role for the transmembrane domain in the trimerization of the MHC class II-Associated invariant chain. J. Immunol. 1999 163 (5) 2704-2712. (Pubitemid 29399196)
86. Marks M. S.; Blum J. S.; Cresswell P. Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens. J. Cell Biol. 1990 111 (3) 839-855.
87. Lue H.; Dewor M.; Leng L.; Bucala R.; Bernhagen J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal. 2011 23 (1) 135-144.
88. Bernhagen J.; Krohn R.; Lue H.; Gregory J. L.; Zernecke A.; Koenen R. R.; Dewor M.; Georgiev I.; Schober A.; Leng L.; Kooistra T.; Fingerle-Rowson G.; Ghezzi P.; Kleemann R.; McColl S. R.; Bucala R.; Hickey M. J.; Weber C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 2007 13 (5) 587-596. (Pubitemid 46828480)
89. Basmaciogullari S.; Pacheco B.; Bour S.; Sodroski J. Specific interaction of CXCR4 with CD4 and CD8alpha: functional analysis of the CD4/CXCR4 interaction in the context of HIV-1 envelope glycoprotein-mediated membrane fusion. Virology 2006 353 (1) 52-67. (Pubitemid 44291786)
90. Lapham C. K.; Ouyang J.; Chandrasekhar B.; Nguyen N. Y.; Dimitrov D. S.; Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996 274 (5287) 602-605. (Pubitemid 26360438)
91. Mbemba E.; Saffar L.; Gattegno L. Role of N-glycans and SDF-1alpha on the coassociation of CD4 with CXCR4 at the plasma membrane of monocytic cells and blood lymphocytes. FEBS. Lett. 2002 514 (2-3) 209-213. (Pubitemid 34273941)
92. Zaitseva M.; Romantseva T.; Manischewitz J.; Wang J.; Goucher D.; Golding H. Increased CXCR4-dependent HIV-1 fusion in activated T cells: role of CD4/CXCR4 association. J. Leukoc. Biol. 2005 78 (6) 1306-1317. (Pubitemid 41779237)
93. Sloane A. J.; Raso V.; Dimitrov D. S.; Xiao X.; Deo S.; Muljadi N.; Restuccia D.; Turville S.; Kearney C.; Broder C. C.; Zoellner H.; Cunningham A. L.; Bendall L.; Lynch G. W. Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunol. Cell. Biol. 2005 83 (2) 129-143. (Pubitemid 40469320)
94. Xiao X.; Wu L.; Stantchev T. S.; Feng Y. R.; Ugolini S.; Chen H.; Shen Z.; Riley J. L.; Broder C. C.; Sattentau Q. J.; Dimitrov D. S. Constitutive cell surface association between CD4 and CCR5. Proc. Natl. Acad. Sci. USA. 1999 96 (13) 7496-7501. (Pubitemid 29299690)
95. Herrera C.; Morimoto C.; Blanco J.; Mallol J.; Arenzana F.; Lluis C.; Franco R. Comodulation of CXCR4 and CD26 in human lymphocytes. J. Biol. Chem. 2001 276 (22) 19532-19539.
96. Oravecz T.; Pall M.; Roderiquez G.; Gorrell M. D.; Ditto M.; Nguyen N. Y.; Boykins R.; Unsworth E.; Norcross M. A. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 1997 186 (11) 1865-1872. (Pubitemid 27524596)
97. Proost P.; Struyf S.; Schols D.; Durinx C.; Wuyts A.; Lenaerts J. P.; De Clercq E.; De Meester I.; Van Damme J. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS. Lett. 1998 432 (1-2) 73-76. (Pubitemid 28360743)
98. Havre P. A.; Abe M.; Urasaki Y.; Ohnuma K.; Morimoto C.; Dang N. H. The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci. 2008 13 1634-1645. (Pubitemid 351599721)
99. Kajiyama H.; Kikkawa F.; Ino K.; Shibata K.; Mizutani S. Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade. Adv. Exp. Med. Biol. 2003 524 245-248. (Pubitemid 36570832)
100. Christopherson K. W. 2nd; Hangoc G.; Broxmeyer H. E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 2002 169 (12) 7000-7008. (Pubitemid 36899288)
101. Sun Y. X.; Pedersen E. A.; Shiozawa Y.; Havens A. M.; Jung Y.; Wang J.; Pienta K. J.; Taichman R. S. CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin. Exp. Metastasis. 2008 25 (7) 765-776.
102. Mentlein R.; Schiemann F.; Ludwig A.; Brandt E. Modification of the biological activity of chemokines by dipeptidyl peptidase IV-A side effect in the use of inhibitors? Adv. Exp. Med. Biol. 2003 524 37-47. (Pubitemid 36570807)
103. Kumar A.; Humphreys T. D.; Kremer K. N.; Bramati P. S.; Bradfield L.; Edgar C. E.; Hedin K. E. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity 2006 25 (2) 213-224. (Pubitemid 44224150)
104. Tilton B.; Ho L.; Oberlin E.; Loetscher P.; Baleux F.; Clark-Lewis I.; Thelen M. Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes. J. Exp. Med. 2000 192 (3) 313-324. (Pubitemid 30629157)
105. Kremer K. N.; Humphreys T. D.; Kumar A.; Qian N. X.; Hedin K. E. Distinct role of ZAP-70 and Src homology 2 domaincontaining leukocyte protein of 76 kDa in the prolonged activation of extracellular signal-regulated protein kinase by the stromal cellderived factor-1 alpha/CXCL12 chemokine. J. Immunol. 2003 171 (1) 360-367. (Pubitemid 36745309)
106. Kremer K. N.; Clift I. C.; Miamen A. G.; Bamidele A. O.; Qian N. X.; Humphreys T. D.; Hedin K. E. Stromal cell-derived factor-1 signaling via the CXCR4-TCR heterodimer requires phospholipase C-beta3 and phospholipase C-gamma1 for distinct cellular responses. J. Immunol. 2011 187 (3) 1440-1447.
107. Barnes P.J. Receptor heterodimerization: A new level of crosstalk. J. Clin. Invest. 2006 116 (5) 1210-1212.
108. Decaillot F.M.; Kazmi M.A.; Lin Y.; Ray-Saha S.; Sakmar T.P.; Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-Arrestin to enhance cell migration. J. Biol. Chem. 2011 286 (37) 32188-32197.
109. Ulvmar M.H.; Hub E.; Rot A. Atypical chemokine receptors. Exp. Cell Res. 2011 317 (5) 556-568.
110. Graham G.J.; Locati M.; Mantovani A.; Rot A.; Thelen M. The biochemistry and biology of the atypical chemokine receptors. Immunol. Lett. 2012 145 (1-2) 30-38.
111. Pruenster M.; Rot A. Throwing light on DARC. Biochem. Soc. Trans. 2006 34 (Pt 6) 1005-1008. (Pubitemid 46768977)
112. Rot A. Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev. 2005 16 (6) 687-694. (Pubitemid 41505524)
113. Chakera A.; Seeber R.M.; John A.E.; Eidne K.A.; Greaves D.R. The duffy antigen/receptor for chemokines exists in an oligomeric form in living cells and functionally antagonizes CCR5 signaling through hetero-oligomerization. Mol. Pharmacol. 2008 73 (5) 1362-1370. (Pubitemid 351574826)
114. Feng Y.; Broder C.C.; Kennedy P.E.; Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996 272 (5263) 872-877. (Pubitemid 26154590)
115. Doranz B. J.; Rucker J.; Yi Y.; Smyth R. J.; Samson M.; Peiper S. C.; Parmentier M.; Collman R. G.; Doms R. W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5 CKR-3 and CKR-2b as fusion cofactors. Cell 1996 85 (7) 1149-1158. (Pubitemid 26235280)
116. Pease J. E.; Horuk R. Chemokine receptor antagonists: part 2. Expert Opin. Ther. Pat. 2009 19 (2) 199-221.
117. Pease J. E.; Horuk R. Chemokine receptor antagonists: part 1. Expert Opin. Ther. Pat. 2009 19 (1) 39-58.
118. Fatkenheuer G.; Pozniak A. L.; Johnson M. A.; Plettenberg A.; Staszewski S.; Hoepelman A. I.; Saag M. S.; Goebel F. D.; Rockstroh J. K.; Dezube B. J.; Jenkins T. M.; Medhurst C.; Sullivan J. F.; Ridgway C.; Abel S.; James I. T.; Youle M.; van der Ryst E. Efficacy of short-term monotherapy with maraviroc a new CCR5 antagonist in patients infected with HIV-1. Nat. Med. 2005 11 (11) 1170-1172. (Pubitemid 43093663)
119. Dorr P.; Westby M.; Dobbs S.; Griffin P.; Irvine B.; Macartney M.; Mori J.; Rickett G.; Smith-Burchnell C.; Napier C.; Webster R.; Armour D.; Price D.; Stammen B.; Wood A.; Perros M. Maraviroc (UK-427,857) a potent orally bioavailable and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005 49 (11) 4721-4732. (Pubitemid 41552605)
120. Bertini R.; Allegretti M.; Bizzarri C.; Moriconi A.; Locati M.; Zampella G.; Cervellera M. N.; Di Cioccio V.; Cesta M. C.; Galliera E.; Martinez F. O.; Di Bitondo R.; Troiani G.; Sabbatini V.; D'Anniballe G.; Anacardio R.; Cutrin J. C.; Cavalieri B.; Mainiero F.; Strippoli R.; Villa P.; Di Girolamo M.; Martin F.; Gentile M.; Santoni A.; Corda D.; Poli G.; Mantovani A.; Ghezzi P.; Colotta F. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA. 2004 101 (32) 11791-11796. (Pubitemid 39095373)
121. Villa P.; Triulzi S.; Cavalieri B.; Di Bitondo R.; Bertini R.; Barbera S.; Bigini P.; Mennini T.; Gelosa P.; Tremoli E.; Sironi L.; Ghezzi P. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol. Med. 2007 13 (3-4) 125-133. (Pubitemid 46944954)
122. Beech J.S.; Reckless J.; Mosedale D.E.; Grainger D.J.; Williams S.C.; Menon D.K. Neuroprotection in ischemia-reperfusion injury: An antiinflammatory approach using a novel broad-spectrum chemokine inhibitor. J. Cereb. Blood Flow Metab. 2001 21 (6) 683-689. (Pubitemid 32510456)
123. Gonsiorek W.; Fan X.; Hesk D.; Fossetta J.; Qiu H.; Jakway J.; Billah M.; Dwyer M.; Chao J.; Deno G.; Taveras A.; Lundell D.J.; Hipkin R.W. Pharmacological characterization of Sch527123 a potent allosteric CXCR1/CXCR2 antagonist. J. Pharmacol. Exp. Ther. 2007 322 (2) 477-485. (Pubitemid 47105793)
124. Chapman R. W.; Minnicozzi M.; Celly C. S.; Phillips J. E.; Kung T. T.; Hipkin R. W.; Fan X.; Rindgen D.; Deno G.; Bond R.; Gonsiorek W.; Billah M. M.; Fine J. S.; Hey J. A. A novel orally active CXCR1/2 receptor antagonist Sch527123 inhibits neutrophil recruitment mucus production and goblet cell hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. Ther. 2007 322 (2) 486-493. (Pubitemid 47105794)
125. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J. Leukoc. Biol. 2010 88 (1) 41-55.
126. Yang Y. F.; Mukai T.; Gao P.; Yamaguchi N.; Ono S.; Iwaki H.; Obika S.; Imanishi T.; Tsujimura T.; Hamaoka T.; Fujiwara H. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anticollagen T cell responses. Eur. J. Immunol. 2002 32 (8) 2124-2132. (Pubitemid 34965875)
127. Tokuyama H.; Ueha S.; Kurachi M.; Matsushima K.; Moriyasu F.; Blumberg R. S.; Kakimi K. The simultaneous blockade of chemokine receptors CCR2 CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int. Immunol. 2005 17 (8) 1023-1034. (Pubitemid 41158385)
128. Akashi S.; Sho M.; Kashizuka H.; Hamada K.; Ikeda N.; Kuzumoto Y.; Tsurui Y.; Nomi T.; Mizuno T.; Kanehiro H.; Hisanaga M.; Ko S.; Nakajima Y. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005 80 (3) 378-384. (Pubitemid 41129967)
129. van Wanrooij E. J.; Happe H.; Hauer A. D.; de Vos P.; Imanishi T.; Fujiwara H.; van Berkel T. J.; Kuiper J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005 25 (12) 2642-2647. (Pubitemid 43732291)
130. Kraemer S.; Lue H.; Zernecke A.; Kapurniotu A.; Andreetto E.; Frank R.; Lennartz B.; Weber C.; Bernhagen J. MIFchemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB. J. 2011 25 (3) 894-906.
131. Greven D.; Leng L.; Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin. Ther. Targets. 2010 14 (3) 253-264.
132. Cournia Z.; Leng L.; Gandavadi S.; Du X.; Bucala R.; Jorgensen W. L. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J. Med. Chem. 2009 52 (2) 416-424.
133. Jorgensen W. L.; Trofimov A.; Du X.; Hare A. A.; Leng L.; Bucala R. Benzisothiazolones as modulators of macrophage migration inhibitory factor. Bioorg. Med. Chem. Lett. 2011 21 (15) 4545-4549.
134. Martinez Munoz L.; Lucas P.; Navarro G.; Checa A. I.; Franco R.; Martinez A. C.; Rodriguez-Frade J. M.; Mellado M. Dynamic regulation of CXCR1 and CXCR2 homo-And heterodimers. J. Immunol. 2009 183 (11) 7337-7346.
135. Rahaman M.; Costello R. W.; Belmonte K. E.; Gendy S. S.; Walsh M. T. Neutrophil sphingosine 1-phosphate and lysophosphatidic acid receptors in pneumonia. Am. J. Respir. Cell Mol. Biol. 2006 34 (2) 233-241. (Pubitemid 43202471)
136. Vischer H. F.; Nijmeijer S.; Smit M. J.; Leurs R. Viral hijacking of human receptors through heterodimerization. Biochem. Biophys. Res. Commun. 2008 377 (1) 93-97.
137. Nijmeijer S.; Leurs R.; Smit M. J.; Vischer H. F. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 heterooligomerizes with human CXCR4 scavenges Galphai proteins and constitutively impairs CXCR4 functioning. J. Biol. Chem. 2010 285 (38) 29632-29641.
138. Bernhagen J.; Krohn R.; Lue H.; Gregory J. L.; Zernecke A.; Koenen R. R.; Dewor M.; Georgiev I.; Schober A.; Leng L.; Kooistra T.; Fingerle-Rowson G.; Ghezzi P.; Kleemann R.; McColl S. R.; Bucala R.; Hickey M. J.; Weber C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 2007 13 (5) 587-596. (Pubitemid 46828480)
139. Triantafilou M.; Lepper P. M.; Briault C. D.; Ahmed M. A.; Dmochowski J. M.; Schumann C.; Triantafilou K. Chemokine receptor 4 (CXCR4) is part of the lipopolysaccharide sensing apparatus. Eur. J. Immunol. 2008 38 (1) 192-203.
140. Toth P. T.; Ren D.; Miller R. J. Regulation of CXCR4 receptor dimerization by the chemokine SDF-1alpha and the HIV-1 coat protein gp120: A fluorescence resonance energy transfer (FRET) study. J. Pharmacol. Exp. Ther. 2004 310 (1) 8-17. (Pubitemid 38812689)
141. Dukkipati A.; Vaclavikova J.; Waghray D.; Garcia K. C. In vitro reconstitution and preparative purification of complexes between the chemokine receptor CXCR4 and its ligands SDF-1alpha gp120-CD4 and AMD3100. Protein. Expr. Purif. 2006 50 (2) 203-214. (Pubitemid 44716708)